The Lancet
Apr 18, 2015 Volume 385 Number 9977 p1477-1590
http://www.thelancet.com/journals/lancet/issue/current
Articles
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
Hannah Kibuuka, MMed, Nina M Berkowitz, MPH, Monica Millard, MPH, Mary E Enama, MA, Allan Tindikahwa, MPH, Arthur B Sekiziyivu, MSc, Pamela Costner, BSN, Sandra Sitar, MS, Deline Glover, BS, Zonghui Hu, PhD, Gyan Joshi, MPH, Daphne Stanley, MS, Meghan Kunchai, MPH, Leigh Anne Eller, PhD, Robert T Bailer, PhD, Richard A Koup, MD, Gary J Nabel, MD, John R Mascola, MD, Nancy J Sullivan, PhD, Barney S Graham, MD, Mario Roederer, PhD, Nelson L Michael, MD, Merlin L Robb, MD, Dr Julie E Ledgerwood, DO, the RV 247 Study Team
†Members listed at end of report
Published Online: 22 December 2014
Summary
Background
Ebola virus and Marburg virus cause serious disease outbreaks with high case fatality rates. We aimed to assess the safety and immunogenicity of two investigational DNA vaccines, one (EBO vaccine) encoding Ebola virus Zaire and Sudan glycoproteins and one (MAR) encoding Marburg virus glycoprotein.
Methods
RV 247 was a phase 1b, double-blinded, randomised, placebo-controlled clinical trial in Kampala, Uganda to examine the safety and immunogenicity of the EBO and MAR vaccines given individually and concomitantly. Healthy adult volunteers aged 18–50 years were randomly assigned (5:1) to receive three injections of vaccine or placebo at weeks 0, 4, and 8, with vaccine allocations divided equally between three active vaccine groups: EBO vaccine only, MAR vaccine only, and both vaccines. The primary study objective was to investigate the safety and tolerability of the vaccines, as assessed by local and systemic reactogenicity and adverse events. We also assessed immunogenicity on the basis of antibody responses (ELISA) and T-cell responses (ELISpot and intracellular cytokine staining assays) 4 weeks after the third injection. Participants and investigators were masked to group assignment. Analysis was based on the intention-to-treat principle. This trial is registered at ClinicalTrials.gov, number NCT00997607.
Findings
108 participants were enrolled into the study between Nov 2, 2009, and April 15, 2010. All 108 participants received at least one study injection (including 100 who completed the injection schedule) and were included in safety and tolerability analyses; 107 for whom data were available were included in the immunogenicity analyses. Study injections were well tolerated, with no significant differences in local or systemic reactions between groups. The vaccines elicited antibody and T-cell responses specific to the glycoproteins received and we detected no differences between the separate and concomitant use of the two vaccines. 17 of 30 (57%, 95% CI 37–75) participants in the EBO vaccine group had an antibody response to the Ebola Zaire glycoprotein, as did 14 of 30 (47%, 28–66) in the group that received both vaccines. 15 of 30 (50%, 31–69) participants in the EBO vaccine group had an antibody response to the Ebola Sudan glycoprotein, as did 15 of 30 (50%, 31–69) in the group that received both vaccines. Nine of 29 (31%, 15–51) participants in the MAR vaccine groups had an antibody response to the Marburg glycoprotein, as did seven of 30 (23%, 10–42) in the group that received both vaccines. 19 of 30 (63%, 44–80) participants in the EBO vaccine group had a T-cell response to the Ebola Zaire glycoprotein, as did 10 of 30 (33%, 17–53) in the group that received both vaccines. 13 of 30 (43%, 25–63) participants in the EBO vaccine group had a T-cell response to the Ebola Sudan glycoprotein, as did 10 of 30 (33%, 17–53) in the group that received both vaccines. 15 of 29 (52%, 33–71) participants in the MAR vaccine group had a T-cell response to the Marburg glycoprotein, as did 13 of 30 (43%, 25–63) in the group that received both vaccines.
Interpretation
This study is the first Ebola or Marburg vaccine trial done in Africa, and the results show that, given separately or together, both vaccines were well tolerated and elicited antigen-specific humoral and cellular immune responses. These findings have contributed to the accelerated development of more potent Ebola virus vaccines that encode the same wild-type glycoprotein antigens as the EBO vaccine, which are being assessed during the 2014 Ebola virus disease outbreak in west Africa.
Funding
US Department of Defense Infectious Disease Clinical Research Program and US National Institutes of Health Intramural Research Program.
.
Series
Violence against women and girls
Prevention of violence against women and girls: what does the evidence say?
Mary Ellsberg, Diana J Arango, Matthew Morton, Floriza Gennari, Sveinung Kiplesund, Manuel Contreras, Charlotte Watts
The health-systems response to violence against women
Claudia García-Moreno, Kelsey Hegarty, Ana Flavia Lucas d’Oliveira, Jane Koziol-McLain, Manuela Colombini, Gene Feder
From work with men and boys to changes of social norms and reduction of inequities in gender relations: a conceptual shift in prevention of violence against women and girls
Rachel Jewkes, Michael Flood, James Lang
GE2P2 Global :: Knowledge Sharing; Ideas; Operations 